Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 14,853 shares at $25.57 ($381K) on 2026-06-01, disclosed to the SEC on 2026-06-03.
Scheduled sale ($381k) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.57 | 13,253 | $339K | 88.9% |
| 2 | $26.36 | 1,600 | $42K | 11.1% |
| Total | $25.66 avg | 14,853 | $381K | 100% |
| Filing → |
| MAZE | SELL | 2026-09-04 | $270K | — | Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |